Changes in recreational drug use, reasons for those changes and their consequence during and after the COVID-19 pandemic in the UK.

Journal: Comprehensive psychiatry
Published Date:

Abstract

Changes in drug use in the general population during the COVID-19 pandemic and their long-term consequences are not well understood. We employed natural language processing and machine learning to analyse a large dataset of self-reported rates of and reasons for drug use during the pandemic, along with their associations with anxiety, depression and substance use problems post-pandemic. Our findings revealed a transient decrease in drug use at the pandemic's peak, primarily attributed to reduced social opportunities. Conversely, some participants reported increased drug use for self-medication, boredom, and lifestyle disruptions. While users of psychedelics and MDMA had anxiety and depression rates similar to non-users, users of opioid agonists and depressants-representing one in ten active drug users-reported greater mental health challenges post-pandemic. These results suggest that a subset of active drug users with distinct profiles faces elevated risks, particularly for anxiety and depression, and may benefit from targeted support.

Authors

  • Maria Bălăeţ
    Department of Brain Sciences, Imperial College London, London, UK; Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: m.balaet17@imperial.ac.uk.
  • Ana Zadel
    Department of Biology, University of Lund, Sweden.
  • Anne Lingford-Hughes
    Department of Brain Sciences, Imperial College London, London, UK; Division of Psychiatry, Imperial College London, London, UK.
  • Louise M Paterson
    Department of Brain Sciences, Imperial College London, London, UK; Division of Psychiatry, Imperial College London, London, UK.
  • Samuel R Chamberlain
    Department of Psychiatry, University of Cambridge, UK; Cambridge and Peterborough NHS Foundation Trust, Cambridge, UK.
  • William Trender
    Department of Brain Sciences, Imperial College London, London, UK.
  • Peter J Hellyer
    Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Adam Hampshire
    Computational, Cognitive and Clinical Neuroimaging Laboratory, Department of Brain Sciences, Imperial College London, London W12 0NN, UK.